Essity stock weighs margin pressure against Brazil growth move

Published on 11/12/2026 at 10:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Essity stock faces a mixed third quarter as sales rose but adjusted profitability weakened. A Brazil feminine-care deal adds a longer-term growth lever.

Sales Growth Meets Cost Pressure

Third-quarter sales increased, but organic growth remained slightly negative as volume and price-mix effects weakened.
Higher costs reduced adjusted EBITA profitability, while operating cash flow remained strong.
The planned Brazilian feminine-care acquisition is expected to close in the second quarter of 2027, subject to regulatory approval.

Essity B, SE0009922164, Illustration mit AI erstellt.

Essity reported a mixed third quarter on Thursday, October 22, 2026, with higher reported sales, stable volumes and strong cash generation, while cost pressure weighed on profitability. The company also agreed to acquire Kenvue's feminine-care business in Brazil, adding a strategic growth initiative to an uneven operating backdrop.

According to the PR Newswire report, net sales rose 4.1% year over year to SEK 36.060 billion from SEK 34.638 billion. The underlying trend was weaker: organic sales declined 0.3%, with volume down 0.1% and price and mix down 0.2%.

Margins Reflect Higher Costs

EBITA fell to SEK 3.636 billion from SEK 5.152 billion in the year-earlier quarter. Excluding items affecting comparability, EBITA declined to SEK 4.725 billion from SEK 5.056 billion, and the adjusted EBITA margin narrowed to 13.1% from 14.6%.

Essity attributed the pressure to intensifying cost headwinds. Management said the group continued to pursue price increases and efficiency measures to offset higher costs, while sales prices were higher than in the second quarter. The company said cost savings were delivered according to plan and that investments in marketing and customer offerings were supporting the business.

Performance differed across the portfolio. Health and Medical delivered organic growth and good profitability, supported by continued progress in incontinence products and wound care. Consumer Tissue recorded lower sales because of weaker volumes, production-footprint optimization in Latin America and price reductions made in earlier quarters. Professional Hygiene remained profitable, although volume development was not satisfactory.

Brazil Deal Extends Feminine Care

The agreement with Kenvue covers the Carefree, Sempre Livre and o.b. brands in Brazil. Essity said the transaction strengthens its feminine-care position in Latin America and follows its earlier feminine-care acquisition in North America. Completion is expected in the second quarter of 2027 and remains subject to regulatory approval.

Essity described Brazil as a significant opportunity in hygiene and health, where it already has a leading position in incontinence products with TENA. For investors, the transaction offers a route to expand in a category the company considers attractive, but the near-term share story remains tied to the ability to protect margins as input costs rise.

Portfolio Review Adds Another Variable

Essity is also continuing its strategic review of Consumer Tissue. The company said it is evaluating a separation or keeping the business within the group, with the aim of identifying the alternative that offers the strongest long-term value creation for both Consumer Tissue and Essity.

Essity stock traded at 26.14 euros on Lang & Schwarz at 10:33 CET on Thursday, November 12, 2026.